Articles

Navigating through the world of coronary stents is about to become more complex.  A plethora of new products are on the horizon, which will utilize new platforms and alloys and present novel...

April 9, 2011 - The Resolute zotarolimus-eluting stent using a new biocompatible polymer achieved a lower rate of restenosis and in-stent thrombosis compared to the Endeavor stent at 12 months in...

April 8, 2011 – In the largest randomized, multicenter trial to compare drug-eluting stents (DES) and bare-metal stents (BMS) placed in saphenous vein graft lesions, researchers found that DES led...

April 8, 2011 — A study from a South Korean research team found that angioplasty with a sirolimus-eluting stent was non-inferior to coronary artery bypass surgery (CABG) in patients with...

April 6, 2011 – One-year results from the pivotal PLATINUM Workhorse trial were presented at the American College of Cardiology (ACC) Scientific Session in New Orleans. The trial compared the...

April 6, 2011 – A pooled analysis of the SPIRIT II, III, IV and COMPARE trials further reinforces the positive clinical performance of an everolimus eluting coronary stent system.

January 10, 2011 – European CE mark approval was announced today for the Abbott, Absorb drug-eluting bioresorbable coronary stent. It is the first bioresorbable stent to gain regulatory approval...

In the world of endovascular devices, the rule is no longer one size fits all. The recent increase in the variety of stents for percutaneous coronary intervention (PCI) offers the physician of a...

In recent years, many medical device companies saw the underserved lower extremity as an opportunity to enter the market for peripheral artery disease (PAD) treatments. For this reason, device...

Final five-year results from the ENDEAVOR III trial, comparing the Endeavor Zotarolimus-Eluting Coronary Stent to the Cypher Sirolimus-Eluting Coronary Stent, showed Endeavor had lower long-term...